Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer.
Passiglia F, Caparica R, Giovannetti E, Giallombardo M, Listi A, Diana P, Cirrincione G, Caglevic C, Raez LE, Russo A, Rolfo C. Passiglia F, et al. Among authors: giallombardo m. Expert Opin Investig Drugs. 2016;25(4):385-92. doi: 10.1517/13543784.2016.1152261. Epub 2016 Feb 24. Expert Opin Investig Drugs. 2016. PMID: 26881293 Review.
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L. Rolfo C, et al. Among authors: giallombardo m. Expert Opin Investig Drugs. 2015;24(11):1493-500. doi: 10.1517/13543784.2015.1096344. Epub 2015 Oct 12. Expert Opin Investig Drugs. 2015. PMID: 26457764 Review.
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica R, de Castro G Jr, Gil-Bazo I, Caglevic C, Calogero R, Giallombardo M, Santos ES, Raez LE, Rolfo C. Caparica R, et al. Among authors: giallombardo m. Crit Rev Oncol Hematol. 2016 May;101:32-9. doi: 10.1016/j.critrevonc.2016.02.012. Epub 2016 Feb 27. Crit Rev Oncol Hematol. 2016. PMID: 26960735 Free article. Review.
Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C, Grassi M, Raez L, Listi A, Giallombardo M, Bustamante E, Gil-Bazo I, Rolfo C. Caglevic C, et al. Among authors: giallombardo m. Ther Adv Respir Dis. 2015 Aug;9(4):164-72. doi: 10.1177/1753465815579608. Epub 2015 Apr 7. Ther Adv Respir Dis. 2015. PMID: 25855060 Free article. Review.
Exosomes in lung cancer liquid biopsies: Two sides of the same coin?
Rolfo C, Giallombardo M, Reclusa P, Sirera R, Peeters M. Rolfo C, et al. Among authors: giallombardo m. Lung Cancer. 2017 Feb;104:134-135. doi: 10.1016/j.lungcan.2016.11.014. Epub 2016 Nov 18. Lung Cancer. 2017. PMID: 27894607 No abstract available.
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice.
Taverna S, Giallombardo M, Gil-Bazo I, Carreca AP, Castiglia M, Chacártegui J, Araujo A, Alessandro R, Pauwels P, Peeters M, Rolfo C. Taverna S, et al. Among authors: giallombardo m. Oncotarget. 2016 May 10;7(19):28748-60. doi: 10.18632/oncotarget.7638. Oncotarget. 2016. PMID: 26919248 Free PMC article. Review.
Exosome-mediated drug resistance in cancer: the near future is here.
Giallombardo M, Taverna S, Alessandro R, Hong D, Rolfo C. Giallombardo M, et al. Ther Adv Med Oncol. 2016 Sep;8(5):320-2. doi: 10.1177/1758834016648276. Epub 2016 May 12. Ther Adv Med Oncol. 2016. PMID: 27583023 Free PMC article. No abstract available.
18 results